The FDA says many Empower GLP-1 prescriber notes appear repeated verbatim

ON THIS PAGE

1. Key findings
2. The inspection closed ten months before the letter
3. The copies charge rests on the prescriptions
4. Sterile work: two insanitary findings, five CGMP citations
5. Why the replies did not settle it
6. What the letter asks for
7. Limitations
8. Sources

The FDA says the prescriber notes offered in support of Empower Pharmacy's compounded GLP-1 drugs "appear to be repeated verbatim across many records." Notes like these are what can let a pharmacy make something close to an approved drug. The agency's warning letter, dated September 18, 2026, says Empower's products did not meet that condition.

The letter went to Empower Clinic Services, LLC dba Empower Pharmacy, addressed to its founder and chief executive. It comes from the Center for Drug Evaluation and Research. It is the agency's position, not a court ruling, and it gives the pharmacy fifteen working days from receipt to answer.

The inspection closed ten months before the letter

FDA investigators were inside the facility from November 3 to November 14, 2025. They issued the firm a Form FDA 483 on the last day. The firm sent written responses dated December 8, 2025, March 18, 2026 and April 30, 2026. The letter followed on September 18, 2026. In the agency's words, the investigators "noted serious deficiencies in your practices for producing drug products, which put patients at risk."

The copies charge rests on the prescriptions

Section 503A of the FD&C Act exempts compounding by a licensed pharmacist or physician from three requirements: FDA approval, current good manufacturing practice (CGMP), and labeling with adequate directions for use. The exemption comes with conditions. One is that the pharmacy must not regularly compound, or compound in inordinate amounts, drugs that are essentially copies of a commercially available product. A compounded drug is not a copy if a prescriber decides that a change makes a significant difference for an identified patient.

The letter names three products: two tirzepatide and niacinamide products of different volumes and strengths, and one semaglutide and cyanocobalamin product. For each it lists monthly order counts from July to October 2025, twelve lines in all. Every count is blacked out in the posted copy and shown as "(b)(4)". So the central number in the letter is not public. The agency's reading of it is: "The volume of products you are producing suggests that differences between products you are compounding and the FDA-approved products are pretextual."

The letter cites three kinds of evidence:

• orders or prescriptions "that lack any prescriber determination of significant difference from the commercially available product";
• "significant difference" statements that "appear to be repeated verbatim across many records," which the letter says suggests they "may be pre-generated for selection by the prescriber";
• the volume of each product compounded and the orders filled.

It then warns, in general terms, about prescriptions generated "through third-party technology platforms that provide prescribers with pre-selected menu options." It names no platform and does not say Empower used one.

A footnote sets the timing. The FDA says its enforcement discretion for pharmacies compounding copies of these drugs ended on March 5, 2025 for tirzepatide injection products and April 24, 2025 for semaglutide injection products. All four months in the order table fall after both dates. The dispute is not about chemistry. It is about whether a prescriber, for a named patient, actually made the call.

Sterile work: two insanitary findings, five CGMP citations

The insanitary-conditions charge, under section 501(a)(2)(A), stands on its own. The letter says that section applies "regardless of whether drug products you compound meet the conditions of section 503A." It gives two examples. The firm did not run adequate smoke studies under dynamic conditions to show one-way airflow in its ISO 5 area. And its media fills, the test runs that check whether sterile filling stays sterile, "were not performed under the most challenging or stressful conditions."

Because the agency treats the cited products as outside 503A, it also holds them to full CGMP rules. The letter lists five failures, each with its regulation: maintaining equipment that controls aseptic conditions (21 CFR 211.42(c)(10)(vi)); written procedures to prevent microbial contamination, including validation of aseptic and sterilization processes (21 CFR 211.113(b)); the quality control unit's oversight (21 CFR 211.22); monitoring the environment in aseptic areas (21 CFR 211.42(c)(10)(iv)); and written production and process controls (21 CFR 211.100(a)).

Why the replies did not settle it

The letter gives the firm partial credit: "some of your corrective actions appear adequate." Two items did not clear. The firm said a smoke study under Rev. 005 ran from March 30 to April 3, 2026, but by its own account the study "remains in controlled post-execution review," and no final report reached the agency.

The second item is sharper. The firm's summary of a January 2026 media fill said no contamination was seen in any vial. The letter says the vial counts in the underlying records do not appear to match that summary, that several entries are marked "N/A" with no explanation, and that several records were rewritten onto Form Revision 3 because the original results went on the wrong form. Its conclusion: "the claim cannot be supported if records do not clearly demonstrate that all vials were accounted for and inspected." A clean summary over records that do not add up is the finding here, and it is a documentation finding, not a contamination finding.

What the letter asks for

The firm has fifteen working days to set out what it has done. The letter warns of "legal action without further notice, including, without limitation, seizure and injunction," and says its list is "not intended to be an all-inclusive statement of violations."

This is a different kind of case from the August 24 letters to peptide storefronts, each of which carried a single heading built from a website review. This one rests on an inspection, the firm's own records and three rounds of replies.

Limitations

A warning letter states the agency's position and opens a window to respond. It is not an adjudication, and no court has ruled on any of it. This piece reports no reply from the firm to the letter because it establishes none. The order counts are redacted, so the volume behind the copies charge cannot be checked from the public record. The letter names no earlier warning letter to this firm, and this piece does not examine the firm's history with the agency. The pharmacy's own website was not read for this piece, so nothing here describes what it sells or how it operates today. Every reading above rests on the posted text of one letter.

What the pharmacy sends back in fifteen working days is not public. What the agency does next may be.

Sources

The warning letter, at fda.gov, dated September 18, 2026, with a page publication time of September 22, 2026, fetched and read on 2026-09-23: Empower Clinic Services, LLC dba Empower Pharmacy, MARCS-CMS 738238. Every quotation and date above is from that document as posted at that URL on the fetch date. The comparison with the August batch rests on the August 24 letters, which carries its own primary sources.